• Innovent Biologics' wholly owned subsidiary Altruist Biologics supported China's acceptance of a multinational client's biologic drug application for localized manufacturing.
• The National Medical Products Administration granted priority review, shortening the regulatory review timeline for the client's shift from overseas to Chinese manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN83385) on October 29, 2026, and is solely responsible for the information contained therein.